ArticleDiabetes2006
Group 1B phospholipase A2-mediated lysophospholipid absorption directly contributes to postprandial hyperglycemia.
Article in Diabetes, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 84 citations in OpenAlex.
- Liver-Specific Suppression of PLA2G6/iPLAFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Secreted phospholipase A2 regulates intercellular communications by coordinating extracellular phospholipid metabolism.International immunology · 2025Review
- Identification and verification of biomarkers associated with arachidonic acid metabolism in non-alcoholic fatty liver disease.Scientific reports · 2025Article
- Inactivation of Group 1B Phospholipase AInternational journal of molecular sciences · 2023Article
- The Roles of sPLABiomolecules · 2023Review
- A rising tide lifts all MBOATs: recent progress in structural and functional understanding of membrane boundFrontiers in physiology · 2023Review
- Old but New: Group IIA Phospholipase AMetabolites · 2022Review
- Group IIA secreted phospholipase A2 controls skin carcinogenesis and psoriasis by shaping the gut microbiota.JCI insight · 2022Article
- Research progress in the role and mechanism of LPCAT3 in metabolic related diseases and cancer.Journal of Cancer · 2022Review
- Exploration of the Mechanism of Linoleic Acid Metabolism Dysregulation in Metabolic Syndrome.Genetics research · 2022Article
- Secretory Phospholipase A2s in Insulin Resistance and Metabolism.Frontiers in endocrinology · 2021Review
- Updating Phospholipase ABiomolecules · 2020Review
- Hepatic HAX-1 inactivation prevents metabolic diseases by enhancing mitochondrial activity and bile salt export.The Journal of biological chemistry · 2020Article
- Cytotoxic, Antioxidant, and Metabolic Enzyme Inhibitory Activities ofOxidative medicine and cellular longevity · 2020Article
- Group 1B phospholipase ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019Review
- Therapeutic reduction of lysophospholipids in the digestive tract recapitulates the metabolic benefits of bariatric surgery and promotes diabetes remission.Molecular metabolism · 2018Article
- Screening key candidate genes and pathways involved in insulinoma by microarray analysis.Medicine · 2018Observational
- Epithelial-Cell-Derived Phospholipase ACell host & microbe · 2017Article
- Lipoquality control by phospholipase AProceedings of the Japan Academy. Series B, Physical and biological sciences · 2017Review
- A lipidomics study reveals hepatic lipid signatures associating with deficiency of the LDL receptor in a rat model.Biology open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Postprandial hyperglycemia is an early indicator of abnormality in glucose metabolism leading to type 2 diabetes. However, mechanisms that contribute to postprandial hyperglycemia have not been identified. This study showed that mice with targeted inactivation of the group 1B phospholipase A2 (Pla2g1b) gene displayed lower postprandial glycemia than that observed in wild-type mice after being fed a glucose-rich meal. The difference was caused by enhanced postprandial glucose uptake by the liver, heart, and muscle tissues as well as altered postprandial hepatic glucose metabolism in the Pla2g1b-/- mice. These differences were attributed to a fivefold decrease in the amount of dietary phospholipids absorbed as lysophospholipids in Pla2g1b-/- mice compared with that observed in Pla2g1b+/+ mice. Elevating plasma lysophospholipid levels in Pla2g1b-/- mice via intraperitoneal injection resulted in glucose intolerance similar to that exhibited by Pla2g1b+/+ mice. Studies with cultured hepatoma cells revealed that lysophospholipids dose-dependently suppressed insulin-stimulated glycogen synthesis. These results demonstrated that reduction of lysophospholipid absorption enhances insulin-mediated glucose metabolism and is protective against postprandial hyperglycemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.